OpGen

OpGen Net Debt

The Net Debt of OpGen (OPGN) as of Oct 27, 2026 is 1.32 M USD. In the previous year, Net Debt was 11.89 M USD — a change of -88.93% (lower).

Net Debt

1.32 MUSD

YoY

-88.93%

Last updated:

Net Debt of OpGen is 2025 1.32 M USD. Net Debt of OpGen was 2024 11.89 M USD. It decreases by -88.93% lower compared to the previous year.

The OpGen Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-551,218.00 USD
Jan 1, 2018
-2.68 M USD
Jan 1, 2019
2.05 M USD
Jan 1, 2020
9.49 M USD
Jan 1, 2021
-10.90 M USD
Jan 1, 2022
7.40 M USD
Jan 1, 2023
11.89 M USD
Jan 1, 2025
1.32 M USD
The OpGen Net Debt history
YEARNet DebtYoY
1.32 MUSD-88.93%
11.89 MUSD+60.72%
7.40 MUSD-167.87%
-10.90 MUSD-214.90%
9.49 MUSD+363.22%
2.05 MUSD-176.51%
-2.68 MUSD+385.66%
-551,218.00USD-80.05%
-2.76 MUSD-55.33%
-6.18 MUSD-348.36%
2.49 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Net Debt of OpGen is 1.32 M USD in 2025.

Net Debt of OpGen changed from 11.89 M USD to 1.32 M USD, representing a -88.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt OpGen since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen